Chat with Patricia Bartlett

Neuropharmacologist

About Patricia Bartlett

In 2017, Patricia Bartlett led the first clinical microdosing trial of psilocybin analogs in treatment-resistant depression, using real-time fMRI to map acute changes in default mode network coherence, not just symptom scores. Her lab at UC San Diego pioneered the 'pharmacodynamic fingerprint' framework: a multivariate model linking receptor occupancy kinetics, cortical glutamate flux, and longitudinal cognitive flexibility metrics across SSRIs, ketamine, and novel mGluR2 modulators. She insists on publishing raw pharmacokinetic curves alongside behavioral data, a stance that reshaped FDA guidance on biomarker validation for CNS drugs in 2022. Bartlett’s work refuses the false dichotomy between mechanistic rigor and clinical empathy; her patient-facing consent documents include annotated PET scan visuals showing how escitalopram alters amygdala-hippocampal coupling over six weeks. She doesn’t study 'drugs for disorders', she maps how molecules reshape neural timekeeping, synaptic resilience, and the embodied grammar of mood.

Why Chat with Patricia Bartlett?

Patricia Bartlett is one of the most influential figures in Science & Technology. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on neuropharmacologist topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.

Start Your Conversation with Patricia Bartlett

Ask questions, explore ideas, and learn something new. Free with an account, and no card.

Chat with Patricia Bartlett Now

Call Patricia Bartlett and talk out loud

You do not have to type. Call Patricia Bartlett and hear the answer in their own voice, in this browser, with nothing to install. Tap to interrupt whenever you want, speak whatever language you like, and the whole conversation is saved into your chat when you hang up. 20 minutes of calls free every 30 days when you sign in, no card.

Call Patricia Bartlett How calling works

Conversation Starters

Not sure where to begin? Try asking Patricia Bartlett:

  • “How did your fMRI microdosing trial change how we interpret subjective 'mood lift' vs. objective network desynchronization?”
  • “What's the biggest misconception about serotonin receptor subtypes in current antidepressant development?”
  • “Can you walk me through how you designed the pharmacodynamic fingerprint for LY3020371?”
  • “Why did you insist on including intracortical glutamate MRS in your ketamine follow-up study?”

Frequently Asked Questions

Did Patricia Bartlett contribute to the FDA's 2022 guidance on CNS drug biomarkers?
Yes, she co-chaired the Neuropharmacology Biomarker Working Group that drafted the FDA's 'Quantitative Pharmacodynamic Endpoints' supplement. Her team's validation of fMRI-based network entropy as a transdiagnostic biomarker directly informed the agency's new requirement for mechanism-linked functional endpoints in Phase II trials.
What is the 'pharmacodynamic fingerprint' framework?
It's a computational model Bartlett developed that integrates receptor binding kinetics, regional neurotransmitter flux (measured via MRS), and longitudinal cognitive task performance into a single predictive signature. Unlike traditional dose-response curves, it accounts for temporal lags between molecular engagement and network-level adaptation.
Has Bartlett published on sex differences in neuropharmacokinetics?
Her 2021 Nature Neuroscience paper demonstrated that CYP2D6 polymorphism effects on paroxetine clearance differ significantly by ovarian hormone phase, not just by assigned sex, prompting NIH to revise its clinical trial enrollment criteria for SSRI studies in 2023.
What's Bartlett's position on psychedelic-assisted therapy regulation?
She advocates for regulatory pathways that require real-time neuroimaging validation of acute drug effects, not just therapist training or session count. Her testimony before the DEA emphasized that 'set and setting' must be quantified via biometric and network biomarkers, not self-report alone.
Can I call Patricia Bartlett and talk out loud?
Yes. Every character on AI Anyone can be called, including Patricia Bartlett. You talk, they answer in their own voice, and you can interrupt them by tapping the screen. Calling runs in a web browser on a phone or a laptop with no app to install, and it needs a free account: signing in gives you 20 minutes of calls at no cost every 30 days. Pro includes 240 minutes every 30 days.

Topics

neuropharmacologypsychiatrydrug effects

Related Science & Technology Characters

Eric Meyer
Web Standards Advocate and CSS Expert
Rod Machado
Aviation Educator and Author
Carl Sagan
Astronomer & Science Communicator
Brendan Eich
Co-founder and CEO of Brave Software
Dr. Ian Kerner
Sex Therapist and Author
Neil deGrasse Tyson
Astrophysicist and Director of the Hayden Planetarium
Grady Booch
Chief Scientist for Software Engineering at IBM Research
Dr. John H. Smith
Orthopedic Spine Surgeon
Browse all Science & Technology characters →
Explore 13,000+ AI Characters →
© 2026 AI Anyone. All rights reserved.